1 / 34

Infertility Prevention Project Region I June 14-15, 2010 Wells Beach, Maine

Infertility Prevention Project Region I June 14-15, 2010 Wells Beach, Maine. Steven J. Shapiro Infertility Prevention Project Coordinator CDC/NCHHSTP/DSTDP/PTB

zitkalasa
Télécharger la présentation

Infertility Prevention Project Region I June 14-15, 2010 Wells Beach, Maine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infertility Prevention ProjectRegion I June 14-15, 2010Wells Beach, Maine Steven J. Shapiro Infertility Prevention Project Coordinator CDC/NCHHSTP/DSTDP/PTB Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  2. Topics National Infertility Prevention Project: • Budget and Funding • Division Updates • PSCI • Health Care Reform • Chlamydia • National Chlamydia Coalition • Gonorrhea • Performance Measures

  3. Funding Applications • CSPS 2011 • Guidance under development • IPP • Progress on 3% CT Positivity • Targeted GC Burden Calculation and plans • Progress on general objectives • Progress on GC meeting action items • IPP-OPA IAA 2010-2011 • IPP Regional Infrastructure Objectives • Pregnancy-test Only • AI/AN Health Care Delivery Systems

  4. DSTDP Update • STD Treatment Guidelines • Recommended treatment for uncomplicated GC will be increased to 250 mg Ceftriaxone. • Cefixime 400 mg will remain as a recommended therapy • Combination therapy for GC+ • STD Laboratory Guidelines • CT GC and syphilis • Re-testing/Supplemental Testing • GYT • 190K Unique visitors; average time 3 minutes • Just under 40K Toolkit Downloads

  5. PCSI • Funding Opportunity Announcement • Grants.gov CDC-PS10-10175 • “To plan, scale-up, and support the implementation of a syndemic approach to the prevention of HIV/AIDS, viral hepatitis, STD and TB through PCSI activities as described……”Enhancing the Prevention and Control of HIV/AIDS, viral hepatitis, STD and TB in the United States” • Eligibility (2007 Surveillance Data) • 630 AIDS Cases • 225 TB Cases • 900 Syphilis (all stages) Cases • 6760 Gonorrhea Cases • 82 HBV Cases • Webinar May 10th

  6. Health Care Reform What does this mean for CDC, in general, and STD Prevention specifically?

  7. Patient Protection and Affordable Care Act • Mandatory Programs • Prevention and Public Health Fund • Up to 2 Billion dollars annually by 2015 • Can be spent on any prevention, wellness or public health activities authorized in the Public Health Services Act. Section 318 of the PHSA authorizes STD prevention (CSPS); section 318A authorizes IPP. • National Prevention, Health Promotion, and Public Health Council • Advisory in Nature- must create a National Prevention and Health Promotion Strategy

  8. PPACA : New Prevention Programs • CDC • Community Transformation • Epidemiology and Laboratory Capacity • Healthy Aging Living Well • Prevention Research • Improvement of vaccine delivery systems • Office of Women’s Health • HHS • State access to purchase vaccine at federally negotiated prices • Menu labeling (FDA) • Individual Wellness Plan evaluation at FQHCs • Grants to support School-based Health Centers • Evidence based teen pregnancy prevention • Evidence based Abstinence-only programs

  9. PPACA: Other Provisions • Insurance (private) • Required to provide recommended clinical preventive benefits, including vaccinations without cost-sharing • Medicaid and Medicare • Medicare preventative services and USPSTF recommended services (“A” level, maybe “B”) become no cost-sharing; coverage and cost sharing for vaccines unchanged • Tobacco cessation pharmaceuticals and expanded cessation services for pregnant woman are covered • Hospitals required to report rates of healthcare-associated infections (MRSA, VRE, etc) • Public Health Workforce • Loan repayment program, expand fellowship programs (EIS) • Monitoring Key National Health Indicators • Standardizes data collection related to health disparities

  10. Chlamydia

  11. Chlamydia — Rates: Total and by sex: United States, 1989–2008 Note: As of January 2000, all 50 states and the District of Columbia had regulations requiring the reporting of chlamydia cases.

  12. Chlamydia — Rates by state: United States and outlying areas, 2008 Note: The total rate of chlamydia for the United States and outlying areas (Guam, Puerto Rico, and Virgin Islands) was 398.5 per 100,000 population.

  13. Chlamydia — Age- and sex-specific rates: United States, 2008

  14. Chlamydia — Rates by race/ethnicity: United States, 1999–2008

  15. Chlamydia — Prevalence by age group and race/ethnicity froma national survey, 1999–2002 Note: Error bars indicate 95% confidence intervals. SOURCE: National Health and Nutrition Examination Survey. Ann Intern Med 2007;Jul 17;147(2):89-96.

  16. Chlamydia — Positivity among 15- to 24-year-old women tested in family planning clinics by state: United States and outlying areas, 2008 Note: Includes states and outlying areas that reported chlamydia positivity data on at least 500 women aged 15-24 years screened during 2008. DATA SOURCE: Prevalence Monitoring Project (Regional Infertility Prevention Projects), Office of Population Affairs, Local and State STD Control Programs, Centers for Disease Control and Prevention

  17. Chlamydia — Trends in positivity among 15- to 24-year-old women tested in family planning clinics by HHS region, 2004–2008 DATA SOURCE: Prevalence Monitoring Project (Regional Infertility Prevention Projects), Office of Population Affairs, Local andState STD Control Programs, Centers for Disease Control and Prevention

  18. National Chlamydia Coalition • Annual Meeting • December 3-4, 2009 DC • Social Marketing • Sub-Committee Meetings • Research Subcommittee • What can you do? • Chlamydia Screening Priority in Health Care Delivery Systems • Outreach to State Adolescent Health Coordinator • Child Health Indicators for Medicaid and CHIP • EMR Incentives for Medicaid and Medicare

  19. National Chlamydia CoalitionMini Grants: To fund innovative strategies to increase CT screening and follow-up care including partner treatment • College Health Program • Old Dominion (VA) • Sports Health Screenings • Uplift School (IL) • Academic Detailing • Private Providers (IL) • CT screening • Medicaid Managed Care (MI) • Awareness and Screening • PP Greater Washington and North Idaho • CT Model Protocol • AI/AN (Regions VIII & X) • JDC Screenings • Baltimore JDC (MD) • Targeted use of GIS • Adagio Health (PA) • Provider Outreach • NYS providers (Region II) • Plan Development • Coalition Building (MN)

  20. DRIP, DRIP, DRIP

  21. Gonorrhea — Rates: United States, 1941–2008

  22. Gonorrhea — Rates by race/ethnicity: United States, 1999–2008

  23. Gonorrhea • “Incurable gonorrhea may be next superbug” • MSNBC 4-8-2010 • “Emergence of Antibiotic-resistant gonorrhea” • Time (blog) 3-31-2010 • “Gonorrhea mutating into superbug especially in SEAsia” • Pattaya Daily News 4-1-2010 • “Sex Infection gonorrhea becoming drug-resistant” • BBC News 3-29-2010

  24. Gonorrhea • AR GC Laboratory Activities • GISP • Enhanced surveillance in the Far East with WHO • Documented Clinical Cases of resistance to oral cephalosporins • WHO-WPRO Consultations (Manila in April; Bali in May) • Basic research to develop a molecular test that could indicate resistance in NAAT-positive specimens • AR GC Outbreak response plan development • Consultation Atlanta September 14-15 • State-level Outbreak Response Plan Development and Pilots • California, Hawaii, Illinois, New York State and Washington state • Regional Meetings • Monitoring Action Plan progress • Meetings Report Development

  25. Performance Measures • CSPS Project started 1999 • Pilot project 2001 • Set of 12 measures 2005 • Timeliness of Treatment CT and GC in FP clinics • STD Clinics added 2007 • GC Interviews modified 2009 • NCSD Survey Optional Measures • Feasibility. Usefulness and Intent to Use • All CT male and females 15-24 • All Gonorrhea

  26. Performance Measure DataTimeliness of Treatment for CT (14 Days)Prevalence Monitoring Family Planning Sites

  27. Performance Measure DataTimeliness of Treatment for GC (14 Days)Prevalence Monitoring Family Planning Sites

  28. Performance Measure DataTimeliness of Treatment CT and GC (14 Days)STD Sites: 2007-2009

  29. Performance Measure and Morbidity DataChlamydia- All FemalesSTD Sites: 2008

  30. Performance Measure and Morbidity DataGonorrhea- All FemalesSTD Sites: 2008

  31. CSPS-IPP 2009 • Gonorrhea Burden Calculation • Portion of Total IPP funds to be used to target GC screening • Total GC women <26/Total CT GC women <26 • Up to 10% of funds available • Identify venues/providers • High morbidity with limited screening coverage • In geographic catchment areas with high morbidity • Shift resources to those areas

  32. GC Burden Calculation Example • Project Area X • Total IPP funds = $500,000 • Among women 25 and younger (all venues) • 500 Gonorrhea and 10,000 Chlamydia • GC Burden = [500/(10000+500)]X100= 4.76% • IPP Funds to be used • $500,000 X 4.76% = $23,800 • @ $10/test = 2380 tests available for targeting

  33. Questions?

More Related